Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)
 
 • Company Description   
Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

Number of Employees: 683

 
 • Price / Volume Information   
Yesterday's Closing Price: $104.39 Daily Weekly Monthly
20 Day Moving Average: 684,318 shares
Shares Outstanding: 49.24 (millions)
Market Capitalization: $5,139.78 (millions)
Beta: 0.46
52 Week High: $139.13
52 Week Low: $72.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.04% -7.24%
12 Week 5.98% -13.54%
Year To Date 23.38% 16.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
One World Trade Center 22nd Floor
-
NEW YORK,NY 10007
USA
ph: 212-332-3241
fax: 212-320-0245
None http://www.axsome.com
 
 • General Corporate Information   
Officers
Herriot Tabuteau - Chief Executive Officer and Chairman of the Board
Nick Pizzie - Chief Financial Officer
Roger Jeffs - Director
Mark Coleman - Director
Mark Saad - Director

Peer Information
Axsome Therapeutics, Inc. (CORR.)
Axsome Therapeutics, Inc. (RSPI)
Axsome Therapeutics, Inc. (CGXP)
Axsome Therapeutics, Inc. (BGEN)
Axsome Therapeutics, Inc. (GTBP)
Axsome Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 05464T104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 49.24
Most Recent Split Date: (:1)
Beta: 0.46
Market Capitalization: $5,139.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.42 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 45.55% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 96.60
Price/Cash Flow: -
Price / Sales: 11.89
EPS Growth
vs. Year Ago Period: 26.61%
vs. Previous Quarter: 16.67%
Sales Growth
vs. Year Ago Period: 61.95%
vs. Previous Quarter: 2.27%
ROE
06/30/25 - -
03/31/25 - -272.80
12/31/24 - -223.51
ROA
06/30/25 - -
03/31/25 - -36.69
12/31/24 - -39.88
Current Ratio
06/30/25 - -
03/31/25 - 2.03
12/31/24 - 2.11
Quick Ratio
06/30/25 - -
03/31/25 - 1.96
12/31/24 - 2.04
Operating Margin
06/30/25 - -
03/31/25 - -48.29
12/31/24 - -57.49
Net Margin
06/30/25 - -
03/31/25 - -64.39
12/31/24 - -74.47
Pre-Tax Margin
06/30/25 - -
03/31/25 - -64.37
12/31/24 - -74.44
Book Value
06/30/25 - -
03/31/25 - 1.08
12/31/24 - 1.18
Inventory Turnover
06/30/25 - -
03/31/25 - 2.39
12/31/24 - 2.19
Debt-to-Equity
06/30/25 - -
03/31/25 - 3.48
12/31/24 - 3.22
Debt-to-Capital
06/30/25 - -
03/31/25 - 77.67
12/31/24 - 76.31
 

Powered by Zacks Investment Research ©